MedTrace Logo

Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer

NCT06204523 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2024-01-18

No results posted yet for this study

Summary

We envisioned a scenario where the interaction between the ATM-Chk2/ATR-Chk1 pathways and Hippo enables GC cells to overcome chemotherapy-induced death stimuli. First, ATM-Chk2 and ATR-Chk1 were found to be activated across all the GC molecular subtypes. Moreover, a number of genes associated with their basal activation are recurrently mutated or amplified.

Thus, we retrospectively characterized a cohort of GC patients treated with first-line therapy for DDR- and Hippo-related markers, identifying a signature predicting inferior PFS and OS. This exploratory analysis provided the necessary information (frequency of candidate biomarkers and effect difference between groups) for a prospective study with validation purposes, which is the main goal of this trial.

Conditions

Interventions

DIAGNOSTIC_TEST

investigated biomarkers regarding the efficacy of first-line chemotherapy

The present study was designed to generate solid evidence on the predictivity of the investigated biomarkers regarding the efficacy of first-line chemotherapy in patients with GC

Sponsors & Collaborators

  • Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti

    collaborator OTHER

  • Campus Bio-Medico University

    collaborator OTHER

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    collaborator OTHER

  • Azienda Ospedaliera "Sant'Andrea"

    collaborator OTHER

  • University of Roma La Sapienza

    collaborator OTHER

  • Azienda Ospedaliero Universitaria Policlinico Modena

    collaborator OTHER

  • Regina Elena Cancer Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-26
Primary Completion
2023-08-30
Completion
2024-08-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06204523 on ClinicalTrials.gov